Evidence map›Paper›PMID 40943376›Full record

ArticleInternational journal of molecular sciences2025

Mitogenomic Alterations in Breast Cancer: Identification of Potential Biomarkers of Risk and Prognosis.

Carlos Jhovani Pérez-Amado, Amellalli Bazan-Cordoba, Laura Gómez-Romero, Julian Ramírez-Bello, Verónica Bautista-Piña, Alberto Tenorio-Torres, Eva Ruvalcaba-Limón, Felipe Villegas-Carlos, Diana Karen Mendiola-Soto, Alfredo Hidalgo-Miranda and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carlos Jhovani Pérez-AmadoLaboratorio de Innovación y Medicina de Precisión Núcleo "A", Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0002-7594-9224
Amellalli Bazan-CordobaLaboratorio de Innovación y Medicina de Precisión Núcleo "A", Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
Laura Gómez-RomeroSubdirección de Bioinformática, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0001-9685-6492
Julian Ramírez-BelloSubdirección de Investigación Clínica, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-4153-9315
Verónica Bautista-PiñaFundación de Cáncer de Mama, FUCAM, Mexico City 04980, Mexico.
Alberto Tenorio-TorresFundación de Cáncer de Mama, FUCAM, Mexico City 04980, Mexico.
Eva Ruvalcaba-LimónFundación de Cáncer de Mama, FUCAM, Mexico City 04980, Mexico.ORCID 0000-0002-4645-3019
Felipe Villegas-CarlosFundación de Cáncer de Mama, FUCAM, Mexico City 04980, Mexico.
Diana Karen Mendiola-SotoLaboratorio de Innovación y Medicina de Precisión Núcleo "A", Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
Alfredo Hidalgo-MirandaLaboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0003-2315-3977
Silvia Jiménez-MoralesLaboratorio de Innovación y Medicina de Precisión Núcleo "A", Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.ORCID 0000-0002-6590-9712

Funding

National Institute of Genomic Medicine C2_19/2009 and 24/2016/I
6 · The paper itself

Abstract

Alterations in the mitochondrial genome (mtDNA) have been shown to be key in cancer development and could be useful as biomarkers for diagnosis, prognosis, and treatment. To identify mtDNA variants associated with breast cancer, we analyzed the whole mtDNA sequence from paired tissues (tumor-peripheral blood) of women with this malignancy and from peripheral blood samples of healthy women. The mtDNA mutational landscape, heteroplasmy levels of the variants, and mitochondrial ancestry were established. Comparative analysis between cases and controls revealed significant differences in the number and location of variants, as well as in the heteroplasmy levels. Cases showed higher mutation number in

Indexed as

Biomarkers, TumorBreast NeoplasmsDNA, MitochondrialGenome, MitochondrialAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMiddle AgedMutationPrognosisBiomarkers, TumorDNA, Mitochondrialbreast cancercase-control studyhaplogroupsheteroplasmymitochondrial DNAmtDNA biomarkersmtDNA mutations

Identifiers

PMID40943376
PMCPMC12428619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.